ClinicalTrials.gg
RecruitingNCT06918002ElLenUpdated Sep 30, 2026

Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients

A Phase 3 interventional study of Elranatamab and Lenalidomide (Revlimid®) in Multiple Myeloma, Newly Diagnosed, sponsored by Intergroupe Francophone du Myelome. Recruiting at 69 sites in 2 countries. Open to participants aged 18 Years to 69 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Intergroupe Francophone du Myelome · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.
Updated Sep 30, 2026First site in BelgiumSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
824
Allocation
Randomized
Ages
18 Years to 69 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 31 studies testing elranatamab in Multiple Myeloma — 21 open to participants now, 25 under way, 5 of them phase 3. elranatamab · Multiple Myeloma.

Planned enrollment
4th of 31
824 · median 75
Started
2025
with 8 others
Phase 3
5 of 31
4 open now
Primary completion
2036-05
later than 24 of 24 live
Registered
20th of 31
by date
Lead sponsor
1 of 31
Intergroupe Francophone du Myelome

Among the 31 studies testing elranatamab in Multiple Myeloma, this one is the 4th largest by planned enrollment, is one of 9 that started in 2025, is one of 5 in phase 3, reaches primary completion later than 24 of the 24 other live ones, and was the 20th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

21 of the 31 studies testing elranatamab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About elranatamab

elranatamab: first FDA approval 2023 (ELREXFIO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 69 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing elranatamab in Multiple Myeloma, or all of them as a file.
02

Study summary

This study is designed as a multicenter, randomized, parallel groups, open-label, phase 3 study in subjects with untreated newly diagnoses Multiple Myeloma eligible for ASCT.

824 patients will be enrolled in this study from approximately 70 study sites.

The 2 parts in the Treatment Phase are described below.

Part 1: Induction/ASCT/Consolidation Phase (1:1 Randomization)

After the screening period, patients will be randomly allocated (1:1) to either:

  • Arm A (standard of care arm): standard induction therapy with 4 cycles of D-VRd, followed by HDCT (Melphalan) + ASCT, D-VRd consolidation therapy
  • Arm B (experimental arm): standard induction therapy with 4 cycles of D-VRd, followed by elranatamab and lenalidomide consolidation therapy.

Part 2: Maintenance Phase (1:1 Re-randomization) Patients will be re-randomized (1:1) and will enter the Maintenance Phase upon completion of consolidation therapy.

  • Arm C (standard of care arm): daratumumab + lenalidomide approx 2 years. Subjects with a negative MRD (for at least 12 months) after 24 cycles of daratumumab-lenalidomide will discontinue daratumumab and continue with lenalidomide monotherapy until disease progression, or study cut-off date (whichever occurs first).

Subjects who did not achieve MRD negativity for at least 12 months after 24 cycles of daratumumab-lenalidomide will continue to receive daratumumab-lenalidomide until:

  • MRD negativity for at least 12 months is reached. Subjects will then continue with lenalidomide monotherapy until disease progression, or study cut-off date (whichever occurs first).
  • Disease progression
  • Or study cut-off date (whichever occurs first).

    • Arm D (experimental arm): elranatamab. Approx 2 years. Subjects with a negative MRD (for at least 12 months) after receiving M22 administration of elranatamab will discontinue study treatment with elranatamab.

Subjects who did not achieve MRD negativity for at least 12 months after M22 elranatamab administration will continue to receive elranatamab, every 24 weeks, until MRD negativity for at least 12 months is reached, disease progression, or study cut-off date (whichever occurs first).

03

Conditions studied

  • Multiple Myeloma, Newly Diagnosed

Browse trials for

04

Who can participate

Ages eligible
18 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects, aged over 18 but \< 70 years old
  2. Patients have provided voluntary written before performing any study-related procedure.
  3. Patients with newly diagnosed multiple myeloma (NDMM) eligible for high-dose chemotherapy (melphalan) and stem cell transplantation (ASCT).
  4. Patients with documented symptomatic NDMM according to CRAB and/or SLIM criteria, with as defined by:

    • Presence of ≥10% monoclonal plasma cells in the bone marrow OR presence of a -proven plasmacytoma. In addition, the patient must have ≥1 of the following myeloma defining events:

      - Hypercalcemia: serum calcium >0.25 mmol/L (>1 mg/dL) higher than (ULN) or >2.75 mmol/L (>11 mg/dL).

      - Renal insufficiency: \< 40mL/min/1.73 m2 using or serum creatinine >177 μmol/L (>2 mg/dL).

      - Anemia: >2 g/dL below the lower limit of normal (LLN) or hemoglobin \<10 g/dL.

      - Bone lesions: ≥1 osteolytic lesion on skeletal radiography, CT or PET-CT.

      - Clonal bone marrow plasma cell percentage ≥60%.

      - Serum involved/uninvolved free light chain ratio ≥100.

      • More than 1 focal lesion (≥5 mm diameter) on MRI.
    • Measurable disease as defined by serum M-component ≥5 g/L, and/or urine M-component ≥200 mg/24 h and/or serum FLC ≥100 mg/L.
  5. Patient has an (ECOG) performance status (PS) ≤2.
  6. Patients must have clinical laboratory values (within 15 days of initiating induction therapy) as follows:

    • Hemoglobin ≥7.5 g/dL (≥5 mmol/L). Prior red blood cell (RBC) transfusion or the use of recombinant human erythropoietin is permitted.
    • (ANC) ≥1.0 G/L (granulocyte colony stimulating factor [G-CSF] use is permitted).
    • (AST) ≤3 x ULN.
    • Alanine aminotransferase (ALT) ≤ 3 x ULN.
    • Total ≤3 x ULN (except in subjects with congenital bilirubinemia, such as Gilbert syndrome, that require a direct bilirubin ≤3 x ULN).
    • Calculated creatinine clearance ≥40 mL/min/1.73 m².
    • Albumin corrected serum calcium ≤14 mg/dL (\<3.5 mmol/L); or free-ionized calcium ≤6.5 mg/dL (≤1.6 mmol/L).
    • count ≥50 Giga/L for subjects who have \<50% of bone marrow nucleated cells as plasma cells. If not, platelet count >30 G/L (platelets transfusions done during the 15 days before initiating induction therapy are not permitted).
  7. Women of must have a negative serum or urine pregnancy test during the screening period before randomization AND within 3 days before of initiating induction therapy.
  8. Patients must be willing and able to comply with scheduled appointments, treatment plan, laboratory tests, and other study procedures (such as blood transfusion if required, ASCT, IVIG prophylaxis, etc.).

Exclusion criteria

Exclusion Criteria:

  1. Subjects previously treated with any systemic therapy for multiple myeloma. Patients are allowed before or during screening, as far as the total dose received is not >160 mg of dexamethasone (or equivalent) within 14 days before initiating induction therapy. Patients with concurrent radiotherapy within the 14 days before initiating induction therapy are not eligible (If possible, in these cases, enrolment should be deferred).
  2. Subject with ongoing Grade ≥ 3 peripheral sensory or motor neuropathy.
  3. Subject with history of GBS or GBS variants, or history of any Grade ≥3 peripheral motor polyneuropathy.
  4. Subject with a current diagnosis of primary amyloidosis, monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or solitary plasmacytoma.
  5. Subject has a diagnosis of Waldenström's macroglobulinemia, or other conditions in which IgM M-protein is present in the absence of a clonal plasma cell infiltration with lytic bone lesions.
  6. The subject has had plasmapheresis within 14 days of initiating induction therapy.
  7. Subject with clinical signs of meningeal involvement of multiple myeloma.
  8. The subject has plasma cell leukemia (by WHO criterion: ≥5% of plasma cells in the peripheral blood) or POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes).
  9. Subject has any concurrent medical or psychiatric condition or disease (e.g., active systemic infection, uncontrolled diabetes, acute diffuse infiltrative pulmonary disease) that is likely to interfere with the study procedures or results, or that in the opinion of the investigator, would constitute a hazard for participating in this study.
  10. Subject has cardiac disease, including:

    • Subject has had myocardial infarction within 1 year before initiating induction therapy, or currently has an unstable or uncontrolled disease/condition related to or affecting cardiac function (e.g., unstable angina, congestive heart failure, [NYHA] class III IV).
    • Subject has uncontrolled cardiac arrhythmia ( [CTCAE] version 4 grade ≥2) or clinically significant electrocardiography () abnormalities.
    • Subject with a baseline as corrected by Fridericia's formula (QTcF) >470 msec (12-lead ECG).
  11. Subjects taking systemic treatment with strong inhibitors of CYP1A2 (fluvoxamine, enoxacin), strong inhibitors of (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort (millepertuis) within the 14 days before initiating induction therapy.
  12. Known intolerance to steroids, mannitol, pregelatinized starch, sodium stearyl fumarate, histidine (as base and hydrochloride salt), arginine hydrochloride, poloxamer 188, sucrose or any of the other components of study intervention that are not amenable to premedication with steroids and H2 blockers or would prohibit further treatment with these agents.
  13. Known allergies to any of the study medications, their analogues, or in the various formulations.
  14. Subjects who have had major surgery within 2 weeks before study inclusion (signing of the ) OR will not have fully recovered from surgery before initiating induction therapy OR have surgery planned during their study participation. Kyphoplasty and vertebroplasty are not considered as major surgery.
  15. Subjects with any prior or concurrent (other than multiple myeloma) within 5 years of study inclusion study, except for adequately treated basal cell or squamous cell carcinoma of the skin, in situ carcinoma of the cervix, or localized prostate adenocarcinoma diagnosed ≥3 years ago and without evidence of biological failure, or other cancers for which the subject has undergone potentially curative therapy and has without evidence of relapse/recurrence for ≥5 years.
  16. Pregnant or breast-feeding women.

Women that refuse to abstain from heterosexual intercourse or refuse to use adequate during heterosexual intercourse starting at least 4 weeks before initiating induction therapy and continually until at least 4 weeks after discontinuing lenalidomide,90 days after discontinuing daratumumab and 6 months after discontinuing elranatamab.

18. Men with partners of , even men with a successful vasectomy, that refuse to use a condom during intercourse, from initiating induction therapy to ≥4 weeks ys after discontinuing lenalidomide,. Furthermore, men must agree to not donate sperm during this period.

19. Known positive for or active hepatitis A, B or C: Uncontrolled or active infection: Patients with positive HBsAg and/or HBV DNA

Of note:

Patients can be eligible if anti-HBc IgG positive (with or without positive anti-HBs) but HBsAg and HBV DNA are negative.

o If anti-HBV therapy in relation to prior infection was started before initiation of IMP, the anti-HBV therapy and monitoring should continue throughout the study treatment period.

Patients with negative HBsAg and positive HBV DNA observed during screening period will be evaluated by a specialist for start of anti-viral treatment: study treatment could be proposed if HBV DNA becomes negative, and all the other study criteria are still met.

  • Active infection: positive HCV RNA and negative anti-HCV.

Of note:

Patients with antiviral therapy for HCV started before initiation of IMP and positive HCV antibodies are eligible. The antiviral therapy for HCV should continue throughout the treatment period until seroconversion.

Patients with positive anti-HCV and undetectable HCV RNA without antiviral therapy for HCV are eligible.

20. Patient with an active systemic infection or severe infections requiring parenteral administration of antibiotics.

21. Patients with a gastrointestinal disease/disorder that may significantly impact the absorption of oral treatments.

22. Patients unable or unwilling to undergo antithrombic prophylaxis.

23. A person under guardianship, trusteeship, or deprived of freedom by a judicial or administrative decision.

Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
824 participants (estimated)

Study arms

  • Active comparator
    D-VRD induction, ASCT and D-VRD consolidation (arm A)

    Standard induction therapy with 4 cycles of D-VRd, followed by HDCT (Melphalan) + ASCT, and 2 cycles of D-VRd consolidation therapy

    Drug: Lenalidomide (Revlimid®) · Drug: Daratumumab SC (Darzalex) · Procedure: Autologous Stem Cell Transplantation · Drug: Bortezomib (Velcade®) · Drug: Dexamethasone

  • Experimental
    D-VRD induction followed by elranatamab and lenalidomide consolidation (arm B)

    Standard induction therapy with 4 cycles of D-VRd, followed by elranatamab and lenalidomide consolidation therapy.

    Drug: Elranatamab · Drug: Lenalidomide (Revlimid®) · Drug: Daratumumab SC (Darzalex) · Drug: Bortezomib (Velcade®) · Drug: Dexamethasone

  • Active comparator
    daratumumab + lenalidomide maintenance (Arm C)

    Daratumumab + Lenalidomide for two years (maintenance)

    Drug: Lenalidomide (Revlimid®) · Drug: Daratumumab SC (Darzalex)

  • Experimental
    elranatamab maintenance (Arm D)

    Elranatamab monotherapy for two years (maintenance)

    Drug: Elranatamab

Interventions

  • Elranatamab is given to arm B patients in association with lenalidomide (for consolidation) and arm D patients in monotherapy (for maintenance) as experimental arms

  • In association with daratumumab, bortezomib and dexamethasone (Arm A), in association with elranatamab (Arm B), and in combination with daratumumab in maintenance (Arm C)

  • Daratumumab is given in association with bortezomib, lenalidomide and dexamethasone in induction therapy (all patients) and consolidation arm A

  • ProcedureAutologous Stem Cell Transplantation

    ASCT is performed in consolidation for Arm A patients after induction therapy with D-VRD

  • Bortezomib is given in associtaion with daratumumab, lenalidomide and dexamethasone in induction (all patients) and consolidation Arm A

  • Dexamethasone is given in association with daratumumab, bortezomib and lenalidomide in induction (all patients) and consolidation Arm A

06

What researchers measure

Primary outcomes

  1. Part 1 (induction/consolidation) from Randomization 1 (R1): to assess whether consolidation therapy with elranatamab and lenalidomide is superior to standard of care, in terms of Minimal Residual Disease (MRD) negativity rate

    To assess whether consolidation therapy with elranatamab and lenalidomide is superior to standard of care, in terms of MRD negativity rate.

    Time frame: at end of consolidation, up to 36 months

  2. Part 2 (maintenance) from Randomization 2 (R2): to assess whether maintenance therapy with elranatamab is superior to standard of care, in terms of Progression Free Survival (PFS).

    To assess whether maintenance therapy with elranatamab is superior to standard of care, in terms of PFS.

    Time frame: from the date of second randomization to the date of confirmed PD (IMWG criteria,) or death from any cause, whichever came first, assessed up to 93 monts

  3. Key secondary objectives: Part 1 (induction/consolidation) from R1: to assess whether consolidation therapy with elranatamab and lenalidomide is superior, in terms of PFS

    To assess whether consolidation therapy with elranatamab and lenalidomide is superior, in terms of PFS

    Time frame: PFS defined as the time interval from the date of first randomization to the date of confirmed Progression Disease (IMWG criteria) or death from any cause, whichever occurs first., assessed up to 128 months

  4. Key secondary objectives: Part I (induction/consolidation) from R1: to assess whether consolidation therapy with elranatamab and lenalidomide is superior to standard of care, in terms of Overal Survival (OS)

    To assess whether consolidation therapy with elranatamab and lenalidomide is superior to standard of care, in terms of OS

    Time frame: up to 128 months

Secondary outcomes

  1. Part 1 (induction/consolidation) from R1: to assess the efficacy of consolidation therapy with elranatamab and lenalidomide compared to standard of care

    To assess the efficacy of consolidation therapy with elranatamab and lenalidomide compared to standard of care: Overall response rate (ORR), Very good partial response (VGPR) rate, Complete response (CR) rate

    Time frame: End of consolidation phase, up to 36 months

  2. Part 2 (maintenance) from R2: to assess the efficacy of maintenance therapy with elranatamab

    To assess the efficacy of maintenance therapy with elranatamab: * Overall response rate (ORR) in maintenance * Very good partial response (VGPR) rate in maintenance * Complete response (CR) rate in maintenance

    Time frame: end of maintenance, up to 58 months

  3. assess safety & Tolerability during induction, and during consolidation and maintenance therapy: Adverse events (AE), serious Adrverse events (SAE) and And adverse events of special interest (AESI) rates - Incidence of Treatment-Emergent Adverse Events

    To assess safety during induction, and during consolidation and maintenance therapy: AEs, SAE and AESI rates , Incidence of Treatment-Emergent Adverse Events \[Safety and Tolerability\]

    Time frame: through study completion, up to 128 months

  4. Throughout the study to evaluate the impact of treatment on health-related Quality of Life (QoL) using Rework questionnaire

    To evaluate the impact of treatment on health-related QoL: Rework questionnaire

    Time frame: through study completion, up to 128 months

  5. Part 2 (maintenance) from Randomization 2 (R2): to assess the efficacy of maintenance therapy with elranatamab, Progression Free Survival 2 form Randomization 2

    To assess the efficacy of maintenance therapy with elranatamab: \- PFS of subsequent/next treatment line (PFS2 from R2)

    Time frame: up to 128 months

  6. Part 2 (maintenance) from R2: to assess the efficacy of maintenance therapy with elranatamab, in term of Minimal Residual Disease negativity

    To assess the efficacy of maintenance therapy with elranatamab: \- MRD negativity at 12 months post R2

    Time frame: 12 months post R2, up to 71 months

  7. Throughout the study: to evaluate the impact of treatment on health-related Quality of Life (QoL) using EQ-5D-5L

    To evaluate the impact of treatment on health-related QoL: scale title :EQ-5D-5L , the minimum value is 0 and maximum value is 100 (100 corresponds to the best health that patient can imagine, 0 corresponds to the worst health that patient can imagine

    Time frame: Though study completion, an average of 11 years

  8. Part 2 (maintenance) from R2: To assess the efficacy of maintenance therapy with elranatamab (OS R2)

    To assess the efficacy of maintenance therapy with elranatamab: \- Overall survival from second randomization (OS R2)

    Time frame: up to 128 months

Other outcomes

  1. EXPLORATORY OBJECTIVES: to assess the impact of genomic markers (from Next generation sequencing (NGS) and Whole Genome Sequencing (WGS)) on outcome

    To assess the impact of genomic markers (from NGS and WGS) on outcome: MRD negativity rate as determined by NGS with a sensitivity of at least 10-5 - PFS1 and OS

    Time frame: up to 128 months

  2. EXPLORATORY OBJECTIVES: to assess Immune mechanisms predicting Elra-Len vs ASCT efficacy

    Impact of the microenvironment (Immune mechanisms predicting Elra-Len vs ASCT efficacy) according to outcome (MRD, PFS and OS) rates

    Time frame: up to 128 months

  3. EXPLORATORY OBJECTIVES: to assess the impact of PET imaging parameters/variables on outcome

    rate of PET imaging positive / negative according to outcome (MRD, PFS and OS) rates

    Time frame: End of consolidation phase, up to 36 months

  4. EXPLORATORY OBJECTIVES: To determine influence of M-component measurement assessed by mass spectrometry on outcome

    To determine influence of M-component measurement assessed by mass spectrometry on outcome

    Time frame: up to 128 months

  5. EXPLORATORY OBJECTIVES: To determine influence of circulating tumor cells on outcome in term of PFS1 and OS

    To determine influence of circulating tumor cells on outcome in term of PFS1 and OS

    Time frame: up to 128 months

  6. Exploratory objective :To evaluate the pharmacokinetics (PK) of elranatamab

    Predose and postdose concentrations of elranatamab

    Time frame: up to 128 months

  7. Exploratory objective : To evaluate the immunogenicity of elranatamab

    To evaluate the immunogenicity of elranatamab

    Time frame: up to 128 months

  8. Exploratory objective :To explore correlations between elranatamab exposure and efficacy, safety and biomarker endpoints, if data allow

    To explore correlations between elranatamab exposure and efficacy, safety and biomarker endpoints, if data allow

    Time frame: up to 128 months

  9. exploratory objective : assess treatment discontinuation rates

    To assess treatment discontinuation rates

    Time frame: up to 128 months

07

Study locations

64 of 69 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for May 2036, 130 months after the start.

Of 71 non-industry phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 87 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 108. This study's planned 130 months is above that.

Counting every sponsor, half of 178 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2024
First posted
Apr 9, 2025
StartActual
Jul 9, 2025
Primary completionEst.
May 2036
CompletionEst.
May 2036
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added — first site in Belgium. 3 sites changed recruiting status (3 now recruiting)
Show 3 sites
  • Centre Léon Bérard · Lyon, FranceNot yet recruiting→Recruiting
  • CHU Carémeau, Institut de Cancérologie du Guard · Nîmes, FranceNot yet recruiting→Recruiting
  • CHU Strasbourg · Strasbourg, FranceNot yet recruiting→Recruiting
Show 5 added (5 Belgium)
  • Institut Jules Bordet · Brussels, Belgium
  • Cliniques Universitaires Saint Luc · Brussels, Belgium
  • Grand Hopital Charleroi · Charleroi, Belgium
  • CHU de Liège · Liège, Belgium
  • CHU UCL Namur · Yvoir, Belgium
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    5 sites added — first site in Belgium. 3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • Centre Léon Bérard · Lyon, FranceNot yet recruiting→Recruiting
    • CHU Carémeau, Institut de Cancérologie du Guard · Nîmes, FranceNot yet recruiting→Recruiting
    • CHU Strasbourg · Strasbourg, FranceNot yet recruiting→Recruiting
    Show 5 added (5 Belgium)
    • Institut Jules Bordet · Brussels, Belgium
    • Cliniques Universitaires Saint Luc · Brussels, Belgium
    • Grand Hopital Charleroi · Charleroi, Belgium
    • CHU de Liège · Liège, Belgium
    • CHU UCL Namur · Yvoir, Belgium
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06918002
Lead sponsor
Intergroupe Francophone du Myelome
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Apr 9, 2025
Start date
Jul 9, 2025
Primary completion
May 2036 (estimated)
Completion
May 2036 (estimated)
Last update
Sep 30, 2026

Study contacts

Juliette SEON, PharmD
Contact
j.seon@myelome.fr
0140212404
Chanaz LOUNI
study director · The Institute for Functional Medicine
Aurore PERROT, Prof
principal investigator · IUCT Toulouse France
Cyrille TOUZEAU, Prof
principal investigator · CHU Nantes France

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elranatamab · Lenalidomide

Start the discussion